Search results
Results from the WOW.Com Content Network
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver ( hepatic steatosis ), and at least one metabolic risk factor.
These findings indicated that the activation of FFAR3 but not FFAR2 by SC-FAs protects against developing fatty liver disease in mice; [13] [30] they also support studies to determine if FFAR3 has these actions in humans and if FFAR3 activators can be used to treat or prevent human fatty liver diseases such as non-alcoholic fatty liver disease ...
An animal model (short for animal disease model) is a living, non-human, often genetic-engineered animal used during the research and investigation of human disease, for the purpose of better understanding the disease process without the risk of harming a human. Although biological activity in an animal model does not ensure an effect in humans ...
The mRNA transcript of TMEM19 is 5662 base pairs. The TMEM19 transcript was found to be expressed in most tissues but has increased expression in duodenum, kidney, skin, small intestine, and urinary bladder. in a non-alcoholic fatty liver disease (NAFLD) model in cells that were subjected to glucose deficiency or oxidative stress.
Alcoholic liver diseases and non-alcoholic fatty liver disease are two types of conditions associated with liver lipid accumulation. [15] Obesity is related with increase accumulation of lipid droplets in non-adipose tissues causing lipotoxicity. The expression of perlipin 2 at normal level appears necessary to induce obesity in mouse model.
Endoplasmic reticulum stress was reported to play a major role in nonâalcoholic fatty liver disease (NAFLD) induction and progression. High fat diet fed rats showed increased ER stress markers CHOP, XBP1, and GRP78. ER stress is known to activate hepatic de novo lipogenesis, inhibit VLDL secretion, promote insulin resistance and inflammatory ...
Treatment with T0901317 decreases amyloidal beta production in an Alzheimer's disease mouse model. [33] However, both T0901317 and GW3965 have been reported to increase plasma and liver triglycerides in some mice models, indicating that T0901317 and GW3965 may not be a good candidate for a therapeutic agent.
TPCs have been implicated in fatty liver diseases, such as NAFLD and NASH. As TPC2 is a cation channel for endocytotic membrane trafficking, TPCs contribute in trafficking LDL molecules for their breakdown and recycling. This primarily occurs within the liver.